Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCT with Gemcitabine, BCNU, Melphalan and Rituximab for B-Cell Lymphoma
NCT00003397Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Sep 1998
- Primary completion
- Dec 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in B-cell non-Hodgkin lymphoma, sponsored by University of Maryland, Baltimore. Primary endpoint: Event-Free Survival at 2 years. Started Sep 1998; status: completed.
02
Drugs
rituximab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00003397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003397.